BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Bristol Myers (BMY) is focusing on label expansions for drugs like Sotyktu and Opdivo to offset revenue losses from legacy drugs facing generic competition; Sotyktu met its primary endpoint in a late-stage trial for psoriatic arthritis, while the EU approved a subcutaneous formulation of Opdivo across multiple solid tumor indications. Despite these developments, BMY shares have underperformed, declining 8.4% YTD versus the industry's 1.2% growth, and the company trades at a discount with a forward P/E of 7.80x compared to the large-cap pharma industry's 15.71x.

Analysis

Bristol Myers Squibb (BMY) is strategically focused on expanding the labels of key drugs, notably Sotyktu and Opdivo, to mitigate revenue declines from legacy products such as Revlimid and Pomalyst, which are encountering generic competition. A positive development is Sotyktu's success in a late-stage trial, meeting its primary endpoint for active psoriatic arthritis in adults; this drug is already approved for moderate-to-severe plaque psoriasis and is also being evaluated for Sjögren's syndrome and systemic lupus erythematosus. Furthermore, Opdivo has secured European Commission approval for its subcutaneous formulation across multiple solid tumor indications and for a perioperative regimen in high-risk non-small cell lung cancer, adding to an earlier FDA approval for Opdivo combined with Yervoy for unresectable or metastatic hepatocellular carcinoma. Despite these pipeline advancements, BMY faces significant competitive pressures: Sotyktu contends with Amgen's (AMGN) Otezla in the psoriasis market, while Opdivo, a key component of BMY's Growth Portfolio, competes against Merck's (MRK) blockbuster Keytruda, which dominates the immuno-oncology sector and accounts for about 50% of MRK's pharmaceutical sales. Financially, BMY's shares have underperformed, declining 8.4% year-to-date compared to the large-cap pharma industry's 1.2% growth. The company trades at a discounted forward price-to-earnings ratio of 7.80x, below its mean of 8.55x and the industry average of 15.71x. Analyst sentiment reflects some uncertainty, with the Zacks Consensus Estimate for 2025 earnings per share revised upwards to $6.85 from $6.78 in the past 60 days, while the estimate for 2026 has seen a downward revision. The stock currently holds a Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should carefully evaluate Bristol Myers Squibb's discounted valuation and recent positive clinical data for Sotyktu against the substantial headwinds from generic erosion of its legacy drug revenues and the intense competitive landscape for its growth drivers, Opdivo and Sotyktu.
• Closely monitor upcoming clinical trial readouts for Sotyktu in new indications and Opdivo's market share performance against Keytruda, as these will be pivotal for BMY's future revenue trajectory and stock performance.
• Considering the mixed earnings estimate revisions for 2025 and 2026, the stock's year-to-date underperformance, and its current Zacks Rank #3 (Hold), a cautious stance is advisable, with a focus on BMY's execution capabilities in advancing its pipeline to effectively navigate patent cliffs and competitive threats.